SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 123 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4 | -20.0% | 242 | 0.0% | 0.00% | – |
Q2 2023 | $5 | 0.0% | 242 | 0.0% | 0.00% | – |
Q1 2023 | $5 | -16.7% | 242 | 0.0% | 0.00% | – |
Q4 2022 | $6 | -99.8% | 242 | +44.9% | 0.00% | – |
Q3 2022 | $4,000 | +33.3% | 167 | 0.0% | 0.00% | – |
Q2 2022 | $3,000 | 0.0% | 167 | 0.0% | 0.00% | – |
Q1 2022 | $3,000 | -25.0% | 167 | 0.0% | 0.00% | – |
Q4 2021 | $4,000 | +33.3% | 167 | 0.0% | 0.00% | – |
Q3 2021 | $3,000 | +50.0% | 167 | +79.6% | 0.00% | – |
Q2 2021 | $2,000 | 0.0% | 93 | 0.0% | 0.00% | – |
Q1 2021 | $2,000 | 0.0% | 93 | +20.8% | 0.00% | – |
Q4 2020 | $2,000 | +100.0% | 77 | -43.0% | 0.00% | – |
Q3 2018 | $1,000 | 0.0% | 135 | 0.0% | 0.00% | – |
Q2 2018 | $1,000 | -50.0% | 135 | 0.0% | 0.00% | – |
Q1 2018 | $2,000 | – | 135 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |